Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Endostar with concurrent chemoradiotherapy for locally advanced cervical cancer
ChiCTR2300079203Phase 2Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Dec 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab, endostar and cisplatin in Cervical Cancer (CC), sponsored by Henan Provincial People's Hospital. Primary endpoint: Progression-free survival. Started Dec 2023; status: recruiting.
02
Drugs
envafolimabendostarcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2300079203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079203.